Skip to main content
. 2017 Jan 19;12(1):e0170108. doi: 10.1371/journal.pone.0170108

Fig 1. Effectiveness and disease activity evaluation in the enrolled patients.

Fig 1

This Figure shows: A) and B) the progressive reduction of both DAS28 and SDAI values; C) the disease activity at the first observation and after 12 months of follow up, respectively; E) the EULAR response criteria after 12 months of follow up.